-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On May 24, the official website of the State Food and Drug Administration showed that sunitinib malate capsules of Chia Tai Tianqing Pharmaceutical Group were approved for marketing, and the product was the fourth domestically approved product.
Source: One-click search on Mi Nei.
Data show that sunitinib malate capsules were developed by Pfizer and are used for inoperable advanced renal cell carcinoma, imatinib mesylate treatment failure or intolerable gastrointestinal stromal tumors and unresectable high metastasis Differentiated and advanced pancreatic neuroendocrine tumors.
Sales of sunitinib capsules in Chinese public medical institutions and physical pharmacies in Chinese cities
Source: Mi Nei Net Database
According to data from Minei.
At present, there are 5 manufacturers of sunitinib malate capsules.
Source: official website of the State Food and Drug Administration, Mi Nei.